Abstract |
Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.
|
Authors | Liu Hong, Yu Han, Jinqiang Liu, Lubi Brain |
Journal | Expert review of gastroenterology & hepatology
(Expert Rev Gastroenterol Hepatol)
Vol. 7
Issue 8
Pg. 759-65
(Nov 2013)
ISSN: 1747-4132 [Electronic] England |
PMID | 24134151
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
- FGFR2 protein, human
- Receptor, Fibroblast Growth Factor, Type 2
|
Topics |
- Animals
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Drug Resistance, Neoplasm
- Humans
- Molecular Targeted Therapy
(adverse effects)
- Protein Kinase Inhibitors
(adverse effects, therapeutic use)
- Receptor, Fibroblast Growth Factor, Type 2
(antagonists & inhibitors, metabolism)
- Signal Transduction
(drug effects)
- Stomach Neoplasms
(drug therapy, enzymology, pathology)
|